Effect of enalapril on left ventricular diameters and exercise capacity in asymptomatic or mildly symptomatic patients with regurgitation secondary to mitral valve prolapse or rheumatic heart disease.

Abstract	The effects of 12 months of therapy were evaluated in 47 mildly symptomatic patients with moderate to severe mitral valve regurgitation; 26 patients received enalapril and 21 received a placebo. Enalapril was associated with a significant reduction in left ventricular diameter and mitral regurgitation volume, with no evidence of change in systolic function indexes. However, enalapril did not hinder progressive aerobic impairment to effort.
Authors	Roney O Sampaio, Max Grinberg, João J Leite, Flávio Tarasoutchi, William A Chalela, Marisa Izaki, Guilherme S Spina, Eduardo Giusti Rossi, Charles Mady
Journal	The American journal of cardiology (Am J Cardiol) Vol. 96 Issue 1 Pg. 117-21 (Jul 01 2005) ISSN: 0002-9149 [Print] United States
PMID	15979448 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References	Angiotensin-Converting Enzyme Inhibitors Placebos Enalapril
Topics	Adult Angiotensin-Converting Enzyme Inhibitors (pharmacology, therapeutic use) Double-Blind Method Drug Administration Schedule Enalapril (pharmacology, therapeutic use) Exercise Tolerance Female Humans Male Middle Aged Mitral Valve Insufficiency (complications) Mitral Valve Prolapse (complications) Placebos Rheumatic Heart Disease (complications) Severity of Illness Index Treatment Outcome Ventricular Remodeling

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!